Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig as Consolidation Therapy in CLL/SLL With Unmutated IGHV
NCT07509151Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Aug 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of surovatamig in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and Serious Adverse Events at 5 years, Progression Free Survival at 5 years and 1 more. Started May 2026; status: recruiting.
02
Drugs
surovatamig
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07509151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509151.